Page last updated: 2024-09-03

alanylglutamine and Angiogenesis, Pathologic

alanylglutamine has been researched along with Angiogenesis, Pathologic in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Beelen, RH; Ferrantelli, E; Foster, TL; Keuning, ED; Liappas, G; Lopéz-Cabrera, M; Vervloet, MG; Vila Cuenca, M	1

Other Studies

1 other study(ies) available for alanylglutamine and Angiogenesis, Pathologic

Article	Year
The dipeptide alanyl-glutamine ameliorates peritoneal fibrosis and attenuates IL-17 dependent pathways during peritoneal dialysis. Kidney international, 2016, Volume: 89, Issue:3 Topics: Animals; Biomarkers; Cytoprotection; Dipeptides; Disease Models, Animal; Epithelial-Mesenchymal Transition; Extracellular Matrix; Female; Inflammation Mediators; Interleukin-17; Male; Mice, Inbred C57BL; Neovascularization, Pathologic; Peritoneal Dialysis; Peritoneal Fibrosis; Peritoneum; Protective Agents; Rats, Wistar; Signal Transduction	2016

Article

Year

The dipeptide alanyl-glutamine ameliorates peritoneal fibrosis and attenuates IL-17 dependent pathways during peritoneal dialysis.

Kidney international, 2016, Volume: 89, Issue:3

Topics: Animals; Biomarkers; Cytoprotection; Dipeptides; Disease Models, Animal; Epithelial-Mesenchymal Transition; Extracellular Matrix; Female; Inflammation Mediators; Interleukin-17; Male; Mice, Inbred C57BL; Neovascularization, Pathologic; Peritoneal Dialysis; Peritoneal Fibrosis; Peritoneum; Protective Agents; Rats, Wistar; Signal Transduction

2016